Skip to main content
SpringerLink
Log in

Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C

  • Original Article
  • Published:
Journal of Infection and Chemotherapy

Abstract

This study was done to evaluate the utility of the Abbott RealTime PCR assay (ART) for the monitoring of chronic hepatitis C patients. The serum samples of 183 patients infected with hepatitis C virus (HCV) genotype 1b who had completed a 48-week period of pegylated interferon (PEG-IFN) alpha-2b plus ribavirin treatment were prospectively analyzed. Serum HCV RNA levels were measured both by ART and by the Roche COBAS Amplicor Monitor test, version2.0 (CAM) at baseline and at weeks 4, 12, 24, 36, and 48 of treatment, and at 24 weeks after the end of treatment (EOT). A significant positive correlation of pretreatment HCV RNA levels was found between ART and CAM (r = 0.595, P < 0.0001). Of the 183 patients, 66 (36.0%) achieved a sustained virological response (SVR). The logarithmic decline of the HCV RNA level from the pretreatment level determined by ART in SVR patients was significantly higher than that in non-SVR patients at all time points tested. The logarithmic decline determined by CAM in SVR patients was significantly higher than that in non-SVR patients only at week 4, but there was no significant difference at other weeks. Of 124 patients who were HCV RNA-negative at EOT by ART, 58 (46.8%) had a relapse of viremia at 24 weeks after EOT, whereas 77 of 143 patients (53.8%) who were HCV RNA-negative at EOT by CAM had a relapse. The relapse rate was lower when determined by ART than by CAM, but not significantly so. ART is more useful than CAM for evaluating the virological response to antiviral treatment for chronic hepatitis C.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Hayashi J, Kishihara Y, Yamaji K, Furusyo N, Yamamoto T, Pae Y, et al. Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection. Hepatology. 1997;25:697–701.

    Google Scholar 

  2. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415–21.

    Article  PubMed  CAS  Google Scholar 

  3. Heim MH. Intracellular signaling and antiviral effects of interferons. Dig Liver Dis. 2000;32:257–63.

    Article  PubMed  CAS  Google Scholar 

  4. Frese M, Dazert E. Interferon-induced effector proteins and hepatitis C virus replication. In: Jirillo E, editor. Hepatitis C virus disease: immunobiology and clinical applications. USA: Springer; 2008. Chapter 6.

  5. Chander G, Sulkowski MS, Jenckes MW, Torbenson MS, Herlong HF, Bass EB, et al. Treatment of chronic hepatitis C. A systematic review. Hepatology. 2002;36:S135–44.

    Article  PubMed  Google Scholar 

  6. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485–92.

    Article  PubMed  CAS  Google Scholar 

  7. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352:1426–32.

    Article  PubMed  CAS  Google Scholar 

  8. Furusyo N, Katoh M, Tanabe Y, Kajiwara E, Maruyama T, Shimono J, et al. Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group. World J Gastroenterol. 2006;12:784–90.

    PubMed  CAS  Google Scholar 

  9. Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Masumoto A, et al. Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients : a project of the Kyushu University Liver Disease Study Group. J Gastroenterol Hepatol. 2008;23:1094–104.

    Article  PubMed  CAS  Google Scholar 

  10. Kainuma M, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, et al. Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C. World J Gastroenterol. 2010;16:4400–9.

    Article  PubMed  CAS  Google Scholar 

  11. Foster GR, Fried MW, Hadziyannis SJ, Messinger D, Freivogel K, Weiland O. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alpha-2a (40KD) and ribavirin. Scand J Gastroenterol. 2007;42:247–55.

    Article  PubMed  CAS  Google Scholar 

  12. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006;43:954–60.

    Article  PubMed  CAS  Google Scholar 

  13. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–55.

    PubMed  CAS  Google Scholar 

  14. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C. Hepatology. 2002; 36:S3–20.

    Google Scholar 

  15. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–82.

    Article  PubMed  CAS  Google Scholar 

  16. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindoller R, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958–65.

    Article  PubMed  CAS  Google Scholar 

  17. Halfon P, Bourliere M, Penaranda G, Khiri H, Ouzan D, et al. Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection. J Clin Microbiol. 2006;44:2507–11.

    Article  PubMed  CAS  Google Scholar 

  18. Sabato MF, Shiffman ML, Langley MR, Wilkinson DS, Ferreira-Gonzalez A. Comparison of performance characteristics of three real-time reverse transcription-PCR test systems for detection and quantification of hepatitis C virus. J Clin Microbiol. 2007;45:2529–36.

    Article  PubMed  CAS  Google Scholar 

  19. Schutten M, Peters D, Back NKT, Beld M, Beuselinck K, Foulongne V, et al. Multicenter evaluation of the new Abbott RealTime assays for quantitative detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol. 2007;45:1712–7.

    Article  PubMed  CAS  Google Scholar 

  20. Michelin BDA, Muller Z, Stelzl E, Marth E, Kessler HH. Evaluation of the Abbott RealTime HCV assay for quantitative detection of hepatitis C virus RNA. J Clin Microbiol. 2007;38:96–100.

    CAS  Google Scholar 

  21. Gerken G, Rothaar T, Rumi MG, Soffredini R, Trippler M, Blunk MJ, et al. Performance of the COBAS AMPLICOR HCV MONITOR test, version 2.0, an automated reverse transcription-PCR quantitative system for hepatitis C virus load determination. J Clin Microbiol. 2000;38:2210–4.

    PubMed  CAS  Google Scholar 

  22. Konnick EQ, Erali M, Ashwood ER, Hillyard DR. Performance characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, Version 2.0, International Unit assay and the National Genetics Institute HCV Superquant assay. J Clin Microbiol. 2002;40:768–73.

    Article  PubMed  CAS  Google Scholar 

  23. Leckie G, Schneider G, Abravaya K, Hoenle R, Johanson J, Lampinen J, et al. Performance attributes of LCx HCV RNA quantitative assay. J Virol Methods. 2004;115:207–15.

    Article  PubMed  CAS  Google Scholar 

  24. Lee SC, Antony A, Lee N, Leibow J, Yang JQ, Soviero S, et al. Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics. J Clin Microbiol. 2000;38:4171–9.

    PubMed  CAS  Google Scholar 

  25. Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N, Ikematsu H, et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol. 1994;89:2151–6.

    PubMed  CAS  Google Scholar 

  26. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645–52.

    Article  PubMed  CAS  Google Scholar 

  27. Pyne MT, Konnick EQ, Phansalkar A, Hillyard DR. Evaluation of the Abbott investigational use only RealTime hepatitis C virus (HCV) assay and comparison to the Roche TaqMan HCV analyte-specific reagent assay. J Clin Microbiol. 2009;47:2872–8.

    Article  PubMed  CAS  Google Scholar 

  28. Matsuura K, Tanaka Y, Hasegawa I, Ohno T, Tokuda H, Kurbanov F, et al. Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients. J Clin Microbiol. 2009;47:385–9.

    Article  PubMed  CAS  Google Scholar 

  29. Fytili P, Tiemann C, Wang C, Schulz S, Schaffer S, Manns MP, et al. Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay. J Clin Virol. 2007;39:308–11.

    Article  PubMed  CAS  Google Scholar 

  30. Ross RS, Viazov SO, Hoffmann S, Roggendorf M. Performance characteristics of a transcription-mediated nucleic acid amplification assay for qualitative detection of hepatitis C virus RNA. J Clin Lab Anal. 2001;15:308–13.

    Article  PubMed  CAS  Google Scholar 

  31. Gerotto M, Dal Pero F, Bortoletto G, Ferrari A, Pistis R, Sebastiani G, et al. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. J Hepatol. 2006;44:83–7.

    Article  PubMed  CAS  Google Scholar 

  32. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology. 2002;122:1554–68.

    Article  PubMed  CAS  Google Scholar 

  33. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436:967–72.

    Article  PubMed  CAS  Google Scholar 

  34. Suzuki T. A hepatitis C virus–host interaction involved in viral replicon: toward the identification of antiviral targets. Jpn J Infect Dis. 2010;63:307–11.

    PubMed  Google Scholar 

  35. Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology. 2004;126:703–14.

    Article  PubMed  CAS  Google Scholar 

  36. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy on interferon-alpha therapy. Science. 1998;282:103–7.

    Article  PubMed  CAS  Google Scholar 

  37. Sulkowski M, Vierling JM, Brown KA, Flamm SL, Kwo P, Mullen KD, et al. Probability of sustained virologic response (SVR) is associated with the magnitude of HCV RNA reduction at week 4 of treatment with peginterferon (PEG) plus ribavirin (RBV): results of the IDEAL trial. Hepatology. 2008;48:1144A (abstract).

    Google Scholar 

  38. Nyberg LM, Shiffman ML, Bonilla H, Hu KQ, Morgan TR, Levine RA, et al. Predicting the ability to achieve a sustained virologic response (SVR) in the first 12 weeks: results from the IDEAL study. Hepatology. 2008;48:1134A (abstract).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Internal Medicine, Kyushu University Hospital, Higashi-Ku, Fukuoka, 812-8582, Japan

    Hiroaki Ikezaki, Norihiro Furusyo, Takeshi Ihara, Takeo Hayashi, Eiichi Ogawa, Kazuhiro Toyoda, Hiroaki Taniai, Mosaburo Kainuma, Masayuki Murata & Jun Hayashi

  2. Department of Environmental Medicine and Infectious Disease, Kyushu University, Fukuoka, Japan

    Hiroaki Ikezaki, Norihiro Furusyo, Takeshi Ihara, Takeo Hayashi, Eiichi Ogawa, Kazuhiro Toyoda, Hiroaki Taniai, Mosaburo Kainuma, Masayuki Murata & Jun Hayashi

Authors
  1. Hiroaki Ikezaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norihiro Furusyo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takeshi Ihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takeo Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eiichi Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuhiro Toyoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroaki Taniai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mosaburo Kainuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masayuki Murata
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jun Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroaki Ikezaki.

About this article

Cite this article

Ikezaki, H., Furusyo, N., Ihara, T. et al. Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C. J Infect Chemother 17, 737–743 (2011). https://doi.org/10.1007/s10156-011-0249-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10156-011-0249-7

Keywords

Search

Navigation